Pharmaceutical Preparations · E9 · CIK 1253689
Clinical-stage biotechnology company developing transformative cancer therapies, including bispecific antibodies and antibody drug conjugates
Comparable business profile · signals at a glance
In the 90 days to Dec 4, 2025: 1 insider bought $18.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 4, 2025 | Harwin Peter EvanDirector,TenPercentOwner | Buy | 1,360,000 | $13.41 | $18.2M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.